• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Cybrexa Therapeutics Inc.

Headquarters: New Haven, CT, United States of America
Website: http://cybrexa.com
Year Founded: 2016
Status: Private

BioCentury | Aug 25, 2023
Management Tracks

John Orwin named chairman at Cargo

Plus: Ramzi Benamar joins Elucida as CFO, and updates from Innoviva and Sarfez
Read More
BioCentury | Apr 14, 2023
Management Tracks

Editas names Reeve chair, adds Levy to board

Plus: Exelixis proposes new directors amid ongoing tussle with activist investor and updates from Jasper, CIRM, Visus, Curemark and more
Read More
BioCentury | Dec 16, 2022
Management Tracks

Resilience hires Rubius, Novartis vet Fisk as CTO

Plus: Seely named president and CEO at Lyell, and updates from Codagenix, Vigil, Hookipa and Cybrexa
Read More
BioCentury | Nov 3, 2022
Deals

Nov. 2 Quick Takes: CSL paying $200M for Arcturus’ mRNA vaccine tech

Plus Rubius seeking alternatives and updates from Horizon, Lilly-Innovent, GSK, Compass, Regeneron, Exelixis, CFIUS and more
Read More
BioCentury | May 20, 2021
Management Tracks

Lurie named U.S. director at CEPI; plus Seres, Celularity, Rain, Senti and Cybrexa

Nicole Lurie was named U.S. director of the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership to develop vaccines for future epidemics. Lurie was assistant secretary
Read More
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

Read More
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

Read More
BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

Akrevia is getting around immunotherapy toxicity by masking biologics until they reach tumor microenvironment
Read More
BioCentury | Jun 21, 2019
Financial News

June 20 Financial Quick Takes: Zymeworks raises $175M; plus Casdin, Scholar Rock and more

Read More
BioCentury | Nov 28, 2018
Emerging Company Profile

Cybrexa: pH-based tumor targeting

How Cybrexa’s delivery platform could reduce PARP inhibitor toxicity in cancer
Read More
Items per page:
1 - 10 of 10